全球自體免疫多腺體症候群 1 型市場（按診斷、治療、劑型、給藥途徑、發病年齡、配銷通路和地區分類）

2025 年全球 1 型自體免疫多腺體症候群市場規模估計為 2.891 億美元，預計到 2032 年將達到 3.628 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 3.3%。

數字。 2025年1型自體免疫多腺體症候群全球市場佔有率（%）（按地區）

自體免疫多內分泌腺症候群 1 型 (APS1)，也稱為自體免疫多內分泌腺病-腺泡病-外胚層營養不良症 (APECED)，是一種罕見的多系統疾病，由腎上腺、副甲狀腺、性腺和其他組織等多個內分泌腺的自體免疫破壞引起。 APS1 是由 AIRE 基因（自體免疫調節劑）突變引起的，該基因控制組織特異性基因的表達並促進中樞耐受誘導。 AIRE功能喪失導致免疫耐受性失敗，引發多器官自體免疫攻擊。 APS1 的常見臨床特徵包括甲狀旁腺功能低下症、原發性腎上腺功能不全、慢性黏膜皮膚念珠菌症和性腺功能障礙。由於 APS1 發病早且嚴重涉及多重器官，因此需要對患者進行終身管理和監測。

市場動態：

由於 APS1 在世界各地的盛行率不斷上升，全球自體免疫多腺體症候群 1 型市場預計將呈現豐厚的成長機會。針對高風險族群的基因篩檢計畫正在提高早期診斷率。加強闡明免疫疾病機制和開發新型耐受誘導療法的研究也在推動市場成長。然而，缺乏核准的標靶藥物和有限的治療選擇繼續阻礙市場的發展。同時，提高人們對罕見疾病的認知並專注於開發新的生技藥品的努力可能會創造有吸引力的機會。作為一種罕見疾病，APS-1 可能受益於孤兒藥資格和其他鼓勵研發的誘因。正在進行的研究旨在提高我們對潛在機制的理解，並實現更有針對性和更有效的治療。然而，有限的患者數量對大規模臨床試驗和藥物開發構成了挑戰。

製藥公司、研究機構和患者權益團體之間的合作對於推進 APS-1 研究和改善患有這種複雜的自體免疫綜合症的人的生活品質至關重要。市場動態受到醫學進步和支持罕見疾病治療的監管環境的影響。

本研究的主要特點

本報告對全球自體免疫多腺體症候群 1 型市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和復合年成長率。

它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。

全球自體免疫多腺體症候群 1 型市場中的關鍵公司是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行介紹的。

研究涉及的主要企業包括輝瑞、GlaxoSmithKline Plc史克、諾華、邁蘭、梯瓦、賽諾菲、羅氏、Zydus 卡迪拉、魯賓、Amneal Pharmaceuticals LLC、西普拉、奧羅拉（Aurora）、Cipla Inc.、Cipla Inc.、Amneal Pharmacesticals LLC、Ciputicals LLC、Flenutical Limited、禮來公司、太陽製藥工業有限公司、艾爾建、百時美施貴寶公司、工業、雅培和 LEO Pharma A/S。

本報告的見解將幫助負責人和企業經營團隊未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和財務分析師。

相關人員可以透過用於分析全球自體免疫多腺體症候群 1 型市場的各種策略矩陣來促進決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管情景
• 服務產品組合
• PEST分析
• 波特分析
• 併購場景
• 管道分析

4. 全球自體免疫多腺體症候群 1 型市場-冠狀病毒 (COVID-19) 大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 全球自體免疫多腺體症候群 1 型市場（依診斷），2020 年至 2032 年

• 血清自體免疫篩檢
• 終末器官功能測試
• 血液檢查

6. 全球自體免疫多腺體症候群 1 型市場（依治療方法分類），2020 年至 2032 年

• 藥品
• 抗真菌劑
• Fluconazole
• Itraconazole
• 骨化三醇
• 皮質類固醇
• 其他（荷爾蒙補充療法等）

7. 2020 年至 2032 年全球 1 型自體免疫免疫多腺體症候群市場（依劑型分類）

• 錠劑
• 膠囊
• 其他

8. 全球自體免疫多腺體症候群 1 型市場（依給藥途徑），2020 年至 2032 年

• 口服
• 其他

9. 2020 年至 2032 年全球 1 型自體免疫免疫多腺體症候群市場（依發病年齡）

• 孩子們
• 成人
• 青春期

第 10 章。 2020 年至 2032 年按分銷管道分類的 1 型自體免疫免疫性多腺體症候群市場

• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章。 2020 年至 2032 年按地區分類的 1 型自體免疫免疫性多腺體症候群市場

• 北美洲
• 歐洲

Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at USD 289.1 Mn in 2025 and is expected to reach USD 362.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.

Figure. Global Autoimmune Polyglandular Syndrome Type 1 Market Share (%), By Region 2025

Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare multisystem disorder caused by the autoimmune destruction of several endocrine glands like the adrenals, parathyroid glands, gonads, and other tissues. APS1 results from mutations in the AIRE gene (autoimmune regulator), which regulates the expression of tissue-specific genes and promotes central tolerance induction. Loss of function of AIRE leads to failures in immune tolerance, leading to autoimmune attacks on multiple organs. Common clinical features of APS1 include hypoparathyroidism, primary adrenal insufficiency, chronic mucocutaneous candidiasis, and gonadal failure. Early onset and severity of multiorgan involvement require lifelong management and monitoring of APS1 patients.

Market Dynamics:

The global autoimmune polyglandular syndrome type 1 market is projected to witness lucrative growth opportunities owing to rising APS1 disease prevalence worldwide. Genetic screening programs for high-risk ethnic populations are driving the early diagnosis rate. Increasing research into understanding immunological disease mechanisms and developing novel tolerance-inducing therapies is also fueling market growth. However, a lack of approved targeted drugs and limited treatment options continue to hamper the market. Meanwhile, initiatives to enhance rare disease awareness and focus on developing new biologics hold potential to create attractive opportunities. As a rare disease, APS-1 may benefit from orphan drug designations and incentives to encourage research and development. Ongoing research aims to deepen our understanding of the underlying mechanisms, allowing for more targeted and effective treatments. However, the limited patient population poses challenges for large-scale clinical trials and drug development.

Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups is crucial for advancing APS-1 research and improving the quality of life for individuals affected by this complex autoimmune syndrome. The market dynamics are influenced by both medical advancements and the regulatory landscape supporting rare disease treatments.

Key features of the study:

This report provides in-depth analysis of the global autoimmune polyglandular syndrome type 1 market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autoimmune polyglandular syndrome type 1 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autoimmune polyglandular syndrome type 1 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autoimmune polyglandular syndrome type 1 market

Detailed Segmentation:

• By Diagnosis
  • Serum Autoimmune Screen
  • End-organ Function Tests
  • Blood Tests
• By Treatment
  • Medication
  • Antifungal Agents
  • Fluconazole
  • Itraconazole
  • Calcitriol
  • Corticosteroids
  • Others (Hormone Replacement Therapy, etc.)
• By Dosage Form
  • Tablet
  • Capsule
  • Others
• By Route of Administration
  • Oral
  • Others
• By Age of Onset
  • Childhood
  • Adult
  • Adolescent
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Key Players:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F.Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increased incidence of autoimmune disorders
  • Growing Genetic Research Insights
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Service offering Portfolio
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Pipeline Analysis

4. Global Autoimmune Polyglandular Syndrome Type 1 Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Serum Autoimmune Screen
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• End-organ Function Tests
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Blood Tests
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Antifungal Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Fluconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Itraconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Calcitriol
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Hormone Replacement Therapy, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tablet
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Capsule
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Childhood
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adolescent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

10. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

11. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product & Service Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Hoffmann-La Roche Ltd.
• Zydus Cadila
• Lupin
• Amneal Pharmaceuticals LLC.
• Cipla Inc.
• Aurobindo Pharma
• Glenmark Pharmaceuticals Limited
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Allergan
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Abbott
• LEO Pharma A/S
• Analyst Views

13. Section

• Research Methodology
• About us